Changes in serum cardiac myosin light chain 1 levels in children with fulminant myocarditis during continuous blood purification

Abstract

Sheng C et al. 904 rev assoC med bras 2017; 63(10):904-909 ORIGINAL ARTICLEChanges in serum cardiac myosin light chain 1 levels in children with fulminant myocarditis during continuous blood purification Before and during treatment (48 and 72 hours after treatment, or death), the optical density value of serum CMLC-1 was measured using enzyme-linked immunosorbent assay, and then the serum CMLC-1 concentration was calculated.The correlations between CMLC-1 OD value change and laboratory indexes including creatine kinase-MB (CK-MB), troponin, myohemoglobin and N-terminal pro-brain natriuretic peptide (NT-proBNP) were analyzed. Results:The serum CMLC-1 concentration significantly increased in the children with FM and decreased obviously during CBP therapy. In the same period, the change of CMLC-1 concentration were positively correlated with creatine kinase-MB (r=0.528), troponin (r=0.726), myohemoglobin (r=0.702), and NT-proBNP levels (r=0.589). Conclusion:The serum CMLC-1 concentration increases significantly in children with FM, but CBP therapy can effectively control this increase.

Fulminant myocarditis in children. Continuous renal replacement therapy to the rescue?

“…1 In a recent issue of Revista da Associação Médica Brasileira, a novel and provocative treatment of FM is proposed based upon the intrinsic involvement of cardiac myosin. 3 Extensive release of cardiac myosin is indeed thought to play a key role in the pathogenesis of FM, in particular by propagating autoimmune-induced myocardial inflammation and subsequent cardiac injury. [4][5][6] Cardiac myosin is an hexamer consisting of two myosin heavy chains, each associated with two myosin light chains, i.c.…”